Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months
January 22, 2024 02:30 ET
|
Abivax
Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months Induction data read-out expected Q1 2025 from the pivotal Phase 3 ABTECT program evaluating obefazimod in...
Abivax 2024 Financial Communication Calendar
January 04, 2024 02:30 ET
|
Abivax
Abivax 2024 Financial Communication Calendar PARIS, France, January 4, 2024, 8:30 a.m. CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage...
Abivax announces the resumption of its liquidity contract
November 21, 2023 02:30 ET
|
Abivax
Abivax announces the resumption of its liquidity contract Paris, France, November 21, 2023 – 8:30 a.m. CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage...
Abivax to participate in the Piper Sandler 35th Annual Healthcare Conference
November 14, 2023 08:00 ET
|
Abivax
PARIS, France, November 14, 2023, 2:00 p.m. CET – Abivax SA (Euronext Paris & Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics...
ABIVAX to Host Key Opinion Leader Luncheon for Investors Focused on Novel Approaches to HIV Therapy
November 22, 2016 15:30 ET
|
ABIVAX
PARIS, Nov. 22, 2016 (GLOBE NEWSWIRE) -- ABIVAX (Euronext Paris: FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral disease, today announced...